Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response

Thompson, Michael A.; Oaks, Martin K.; Singh, Maharaj; Michel, Karen; Mullane, Michael P; Tarawneh, Husam S; Kraut, Angi; Hamm, Kayla J

doi:10.17294/2330-0698.1453

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Такая стратегия также может помочь повысить эффективность вакцинации и увеличить продолжительность иммунной защиты. С клинической точки зрения важно помнить о том, что не было обнаружено очевидной связи между иммунным ответом на пневмококковую вакцинацию и общим уровнем IgG у пациента с ММ на момент введения вакцины [50]. Это согласуется с независимыми выводами о том, что изотипы IgG могут иметь большее значение в ответе на вакцинацию, чем общий уровень IgG [51].…”

Section: обзор Reviewunclassified

Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma

Stoma

2021

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

Relevance. Among the groups at high risk of developing invasive pneumococcal infections, patients with multiple myeloma (MM) stand out among the highest rates of morbidity and mortality due to the presence of profound immunosuppression. Aims: to outline the current state of the problem of vaccine prevention of pneumococcal infection in patients receiving treatment for multiple myeloma, to present the evidence base for vaccination with conjugated pneumococcal vaccine. A continuous data review method was used to evaluate the studies on vaccination approaches against pneumococcal infection in patients with multiple myeloma. Conclusions. The article presents modern epidemiological data, as well as the results of original studies of clinical and immunological aspects of pneumococcal vaccination in patients with MM receiving new targeted agents and immunotherapy. The effectiveness of the use of the conjugated pneumococcal vaccine in patients treated with MM with bortezomib, lenalidomide, and ixazomib was indicated. An independent protective effect of pneumococcal vaccination has been shown as a preventive measure in a cohort of patients with MM, against the background of treatment with new targeted drugs.

show abstract

Section: обзор Reviewunclassified

Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma

Stoma

2021

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

show abstract

“…Other examples of TD and TI antigens (vaccines and infectious agents) are listed in Table 1. Our clinical oncology program has recently developed an interest in vaccination patterns in our large population of myeloma patients, specifically with a focus on influenza and pneumococcal vaccination rates and patient outcomes [20][21][22]. As part of these studies, we hypothesized that the simultaneous administration of checkpoint blockade agents or CD40 agonists would have measurable effects on both TI and TD antibody responses.…”

Section: Journal Of Cancer Research and Immuno-oncologymentioning

confidence: 99%

The Effects of Checkpoint Blockade and a CD40 Agonist on Tindependent and T-dependent Antibody Responses in Mice: Implications for Optimization of Vaccination Strategies in Patients Receiving Immunotherapies

Michel¹,

Gehrand²,

Thompson³

et al. 2018

J Cancer Res Immunooncol

View full text Add to dashboard Cite

Background: Patients with cancer often do not receive vaccines to preventable infectious diseases such as influenza and pneumococcal pneumonia because of a lack of knowledge about the optimal timing of vaccination relative to their underlying disease or their current cancer treatments. Cancer immunotherapies, which rely on the ability to promote immune responsiveness to tumors, are a promising therapeutic modality, but their impact on vaccination is largely unexplored. Methods:We used a pre-clinical mouse model to evaluate the antibody response to a T-dependent (TD) or a Tindependent (TI) antigen immunization with concomitant administration of either checkpoint inhibitors such as antibodies to CTLA-4 or PD-L1 or an antibody to CD40 that has adjuvant properties. Results:We found that checkpoint blockade with anti-CTLA-4 or anti-PD-L1 antibodies provided reduction in IgM, IgG, and most IgG subclasses when immunized with either TI or TD antigens. On the other hand, a CD40 agonist antibody provoked modest reductions in all immunoglobulins in response to TD antigen but provided marked increases in most immunoglobulins and IgG subclasses in response to TI antigen.Conclusions: These data suggest that the timing of vaccinations relative to immunotherapies might be an important factor in determining the efficacy of vaccination. If these findings are shown to extend to humans, the antibody response to vaccination might be attenuated and patients might be at increased risk for infection. This pilot study provides potential mechanistic insights into an important consideration in patients receiving immunotherapies.

show abstract

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Thompson

Boccadoro²,

Leleu³

et al. 2023

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response

Abstract: Journal of Patient-Centered Research and Reviews ( JPCRR) is a peerreviewed scientific journal whose mission is to communicate clinical and bench research findings, with the goal of improving the quality of human health, the care of the individual patient, and the care of populations.

Cited by 3 publications

References 10 publications

Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma

Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma

The Effects of Checkpoint Blockade and a CD40 Agonist on Tindependent and T-dependent Antibody Responses in Mice: Implications for Optimization of Vaccination Strategies in Patients Receiving Immunotherapies

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Contact Info

Product

Resources

About